What is the 13F Pro Quality Score for OVID?

13F Pro ranks Ovid Therapeutics Inc. (OVID) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OVID's current score at https://13fpro.ai/research/OVID (free sign-up required for the full ranking).

Where does 13F Pro source OVID data?

All Ovid Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Ovid Therapeutics Inc. files with the SEC under CIK 1636651. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OVID in?

Ovid Therapeutics Inc. (OVID) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OVID research updated on 13F Pro?

OVID's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ovid Therapeutics Inc.(OVID)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1636651 OVID stock profile & AI dashboard →

13F Pro Quality Score

13.1/100

Rank #2,772 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

4.4/100

Profitability

15.3/100

Balance Sheet

7.7/100

Earnings Quality

30.0/100

Free Cash Flow

14.8/100

Institutional Flow

4.5/100

Revenue Scale

25.9/100

Dilution Risk

4.1/100

OVID Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ovid Therapeutics Inc. (OVID), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OVID at 13.1/100 on a 32-signal composite quality model, placing it at rank #2,772 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (4.4) and institutional flow (4.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Ovid Therapeutics Inc. reports net income of $-17.0M, free cash flow of $-13.9M. Top institutional holders of OVID by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., JANUS HENDERSON GROUP PLC, Affinity Asset Advisors,, based on the most recent SEC filings. OVID trades on the Nasdaq exchange and files with the SEC under CIK 1636651. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OVID daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ovid Therapeutics Inc. directly from SEC EDGAR. Ovid Therapeutics Inc.'s 13F Pro composite quality score has ranged between 5 and 43 since 2021, currently 13.1 — a declining long-term trajectory across 26 quarterly and live scoring snapshots.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-17.0M

Free Cash Flow

Q1 2026

$-13.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-96.7% YoY

$7.3MFY 2025

FY21 $221.0MFY22 $222.5MFY23 $222.8MFY25 $7.3M

Net Income

+66.8% YoY

$-17.4MFY 2025

FY21 $122.8MFY22 $-54.2MFY23 $-52.3MFY25 $-17.4M

Operating Income

+28.4% YoY

$-42.4MFY 2025

FY21 $124.2MFY22 $-55.5MFY23 $-59.3MFY25 $-42.4M

EPS (Diluted)

—FY 2025

FY21 $1.76FY22 $-0.77FY23 $-0.74FY25 —

Total Assets

+4.8% YoY

$150.9MFY 2025

FY21 $194.5MFY22 $155.3MFY23 $144.0MFY25 $150.9M

Op. Cash Flow

+16.3% YoY

$-38.3MFY 2025

FY21 $118.6MFY22 $-55.2MFY23 $-45.8MFY25 $-38.3M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$7.3M -96.7%	$222.8M +0.1%	$222.5M +0.7%	$221.0M +1651.6%	$12.6M	—
Net Income	$-17.4M +66.8%	$-52.3M +3.4%	$-54.2M -144.1%	$122.8M +251.6%	$-81.0M -34.0%	$-60.5M
Operating Income	$-42.4M +28.4%	$-59.3M -6.7%	$-55.5M -144.7%	$124.2M +252.5%	$-81.4M -32.6%	$-61.4M
EPS (Diluted)	—	$-0.74 +3.9%	$-0.77 -143.8%	$1.76 +226.6%	$-1.39	—
Total Assets	$150.9M +4.8%	$144.0M -7.2%	$155.3M -20.2%	$194.5M +156.2%	$75.9M -6.1%	$80.8M
Operating Cash Flow	$-38.3M +16.3%	$-45.8M +17.1%	$-55.2M -146.6%	$118.6M +329.9%	$-51.6M -1.0%	$-51.1M

AI Insight: OVID Financial Trends

Equity surged to $198M in Q1 2026 on capital raises, but operating losses persist near -$18M with zero revenue, signaling continued cash burn.

• Revenue remains effectively zero across nearly all quarters, with the $224M Q1 2025 spike appearing non-recurring and absent in Q1 2026.

• Operating losses widened to -$18M in Q1 2026, the steepest in the observed period, reversing modest improvement seen in Q2 2025 (-$5M).

• Equity jumped from $131M in Q4 2025 to $198M in Q1 2026, suggesting a significant capital raise rather than earnings-driven growth.

⚠ Operating cash outflow held at -$14M in Q1 2026, matching Q2 2024 levels — runway erosion risk without a sustainable revenue catalyst.

⚠ Equity has declined from $89M in Q2 2024 to $45M in Q3 2025 before the Q4 2025 raise — dilution frequency warrants monitoring.

⚠ No debt reported across all quarters — absence of leverage preserves flexibility but equity dilution appears to be the primary funding mechanism.

AI Insight: OVID Ratio Trends

Ovid Therapeutics remains deeply unprofitable with ROE swinging wildly quarter to quarter, reflecting one-off items masking persistent operational losses.

• ROE has swung from +38.3% in Q2 2024 to -108.8% in Q3 2025, signaling no stable earnings base.

• TTM ROA of -10.7% and ROIC of -24.1% confirm the business continues to destroy capital on a trailing basis.

• Q1 2025 is the only quarter with OpMargin data (-5.6%) and NPM (-4.6%), leaving trend visibility severely limited.

⚠ ROE turned positive in Q4 2025 (+29.6%) then collapsed to -34.3% in Q1 2026 — likely one-off driven, not operational improvement.

⚠ Persistent absence of OpMargin and NPM data across most quarters makes fundamental trend analysis impossible to confirm.

Get alerted when OVID's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ovid Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OVID

RA CAPITAL MANAGEMENT, L.P.
$23.8M10,714,000 sh
JANUS HENDERSON GROUP PLC
$23.7M10,714,000 sh
Affinity Asset Advisors, LLC
$23.6M10,636,318 sh
EVENTIDE ASSET MANAGEMENT, LLC
$22.0M9,916,911 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$13.7M6,163,781 sh
BALYASNY ASSET MANAGEMENT L.P.
$12.3M5,533,073 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.7M5,258,246 sh
ADAR1 Capital Management, LLC
$10.1M4,544,113 sh
Saturn V Capital Management LP
$9.2M4,166,666 sh
FEDERATED HERMES, INC.
$7.9M3,571,000 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$23.8M	10,714,000
JANUS HENDERSON GROUP PLC	$23.7M	10,714,000
Affinity Asset Advisors, LLC	$23.6M	10,636,318
EVENTIDE ASSET MANAGEMENT, LLC	$22.0M	9,916,911
ADAGE CAPITAL PARTNERS GP, L.L.C.	$13.7M	6,163,781
BALYASNY ASSET MANAGEMENT L.P.	$12.3M	5,533,073
VANGUARD CAPITAL MANAGEMENT LLC	$11.7M	5,258,246
ADAR1 Capital Management, LLC	$10.1M	4,544,113
Saturn V Capital Management LP	$9.2M	4,166,666
FEDERATED HERMES, INC.	$7.9M	3,571,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OVID on your watchlist

Track score changes the day Ovid Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OVID a good stock to buy?

13F Pro's AI-powered analysis of Ovid Therapeutics Inc. (OVID) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OVID are available on the OVID stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OVID?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OVID. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ovid Therapeutics Inc.'s investment landscape.